Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296796 | 0.94 | ACACB (0.62) | ACACBACACA | |
| SCHEMBL4294128 | 0.88 | ACACB (0.52) | ACACBACACA | |
| SCHEMBL4289542 | 0.85 | ACACB (0.67) | ACACBACACA | |
| SCHEMBL4296840 | 0.80 | ACACB (0.68) | ACACBACACA | |
| SCHEMBL4296629 | 0.77 | ACACB (0.62) | ACACBACACA | |
| SCHEMBL4290222 | 0.76 | ACACB (0.53) | ACACBACACA | |
| SCHEMBL13609484 | 0.74 | ACACB (0.49) | ACACBACACA | |
| SCHEMBL4293424 | 0.72 | ACACB (0.49) | ACACBACACA | |
| SCHEMBL4291636 | 0.71 | ACACB (0.70) | ACACBACACA | |
| SCHEMBL4289525 | 0.71 | ACACB (0.52) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2009011-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TNNC1, CPT1B, TNNI3 | ACACB 23/4885ACACA 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.